00:32 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Daiichi submits Japanese application for esaxerenone

Exelixis Inc. (NASDAQ:EXEL) said Daiichi Sankyo Co. Ltd. (Tokyo:4568) submitted a regulatory application in Japan for esaxerenone (CS-3150) to treat hypertension, triggering a $20 million milestone payment to the South San Francisco company. The candidate...
00:19 , Feb 28, 2018 |  BC Extra  |  Company News

Exelixis shares dip after 4Q earnings

Exelixis Inc. (NASDAQ:EXEL) fell $2.42 to $27.11 on Tuesday after reporting late Monday sales of Cabometyx cabozantinib that fell short of analyst estimates. The company said the renal cell carcinoma drug posted 4Q sales of...
20:45 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Chinese biotech KBP raises $76 million series A

KBP Biosciences Co. Ltd. (Jinan, China) raised a $76 million series A round on Jan. 5 co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay City Capital...
13:06 , Jan 5, 2018 |  BC Extra  |  Financial News

Chinese biotech KBP raises $76 million series A

KBP Biosciences Co. Ltd. (Jinan, China) raised a $76 million series A round co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay City Capital GF XINDE Life...
21:33 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Daiichi planning Japanese application for hypertension candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Exelixis Inc. (NASDAQ:EXEL) said esaxerenone (CS-3150) met the primary endpoint in the Japanese Phase III ESAX-HTN trial to treat essential hypertension. In 1Q18, Daiichi plans to submit a regulatory...
23:33 , Sep 25, 2017 |  BC Extra  |  Clinical News

Daiichi planning Japanese application for hypertension candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Exelixis Inc. (NASDAQ:EXEL) said esaxerenone (CS-3150) met the primary endpoint in the Japanese Phase III ESAX-HTN trial to treat essential hypertension. In 1Q18, Daiichi plans to submit a regulatory...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Esaxerenone: Phase III started

Daiichi began the double-blind, Japanese Phase III ESAX-HTN trial to compare 2.5 and 5 mg oral CS-3150 once daily after breakfast for 12 weeks vs. 50 mg oral eplerenone in about 930 patients. The trial...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

Myo my

Phase II readouts showing that omecamtiv mecarbil improves cardiac output and physiology could translate into better outcomes and quality of life for chronic heart failure patients, if Amgen Inc. and Cytokinetics Inc. decide to move...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Finerenone: Phase IIb data

The double-blind, placebo-controlled, international Phase IIb ARTS-HF trial in about 1,058 patients who presented to an emergency department with worsening CHF with reduced ejection fraction and Type II diabetes and/or chronic kidney disease (CKD) showed...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

AstraZeneca, INSERM deal

AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K.   French National Institute of Health and Medical Research , Paris, France   Business: Renal, Endocrine/Metabolic   AstraZeneca and The French National Institute of Health and Medical Research (Inserm) partnered...